At the recent American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancer Symposium, Dr. Josep Tabernero, Director of the Vall d'Hebron Institute of Oncology, presented results of the phase 3 SUNLIGHT trial of trifluridine/tipiracil plus bevacizumab for patients with metastatic colorectal cancer. In this interview, Dr. Tabernero further elaborates on the significance of this treatment combination and its emerging role in the treatment landscape.
At this weekend's American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancer Symposium, Dr. Josep Tabernero, Director of the Vall d'Hebron Institute of Oncology, presented results of the phase 3 SUNLIGHT trial of trifluridine/tipiracil plus bevacizumab for patients with metastatic colorectal cancer. In this interview, Dr. Tabernero further elaborates on the significance of this treatment combination and its emerging role in the treatment landscape.
At the recent American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, Dr. Augusto Villanueva, an Associate Professor of Medicine at Mount Sinai Hospital, discussed the role of the four main etiologies of hepatocellular carcinoma (HCC) in the response that patients may experience to treatment with immune checkpoint inhibitors. In this interview, Dr. Villanueva delves further into the question of whether etiology should play a part in immune-based treatment selection, as well as the role of liquid biopsy for patients newly diagnosed with HCC.
Treatment options are limited for patients with metastatic colorectal cancer who have microsatellite-stable disease, which renders them ineligible for immune checkpoint inhibitor therapy. In a cohort of the COSMIC-021 trial, a team of researchers led by Dr. Thomas Abrams, Assistant Professor of Medicine at Harvard Medical School, investigated the efficacy of cabozantinib plus atezolizumab for this patient population. Dr. Abrams recently presented the trial's results at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium. In this interview, he discusses the role that cabozantinib/atezolizumab may play for patients with metastatic colorectal cancer, particularly those with RAS wild-type disease, in the coming years.
At the recent American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, Dr. Augusto Villanueva, an Associate Professor of Medicine at Mount Sinai Hospital, discussed the role of the four main etiologies of hepatocellular carcinoma (HCC) in the response that patients may experience to treatment with immune checkpoint inhibitors. In this interview, Dr. Villanueva delves further into the question of whether etiology should play a part in immune-based treatment selection, as well as the role of liquid biopsy for patients newly diagnosed with HCC.
Treatment options are limited for patients with metastatic colorectal cancer who have microsatellite-stable disease, which renders them ineligible for immune checkpoint inhibitor therapy. In a cohort of the COSMIC-021 trial, a team of researchers led by Dr. Thomas Abrams, Assistant Professor of Medicine at Harvard Medical School, investigated the efficacy of cabozantinib plus atezolizumab for this patient population. Dr. Abrams recently presented the trial's results at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium. In this interview, he discusses the role that cabozantinib/atezolizumab may play for patients with metastatic colorectal cancer, particularly those with RAS wild-type disease, in the coming years.
For patients with gastric and gastroesophageal cancers, questions remain in the optimal approaches to treatment and surgery. At the recent American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, Ryan Fields, MD, Chief of the Section of Surgical Oncology at Washington University School of Medicine and the Alvin J. Siteman Cancer Center, discussed recent developments in the surgical approach to these diseases. In this interview with Oncology Data Advisor, Dr. Fields delves...